Zacks Research Has Positive Forecast for TSE:BHC Q2 Earnings

Bausch Health Companies Inc. (TSE:BHC) – Analysts at Zacks Research upped their Q2 2025 earnings estimates for shares of Bausch Health Companies in a report issued on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.52 for the quarter, up from their previous forecast of $1.49. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2025 earnings at $1.67 EPS, Q1 2026 earnings at $1.59 EPS, Q4 2026 earnings at $1.80 EPS, FY2026 earnings at $6.84 EPS and FY2027 earnings at $8.21 EPS.

Bausch Health Companies Stock Up 3.1 %

TSE BHC opened at C$10.27 on Thursday. Bausch Health Companies has a twelve month low of C$5.45 and a twelve month high of C$15.43. The stock has a market cap of C$2.67 billion, a PE ratio of -15.03, a PEG ratio of 0.21 and a beta of 0.77. The firm has a 50-day simple moving average of C$10.37 and a 200 day simple moving average of C$10.59. The company has a debt-to-equity ratio of -1,831.94, a quick ratio of 0.58 and a current ratio of 1.19.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.